Holen Sie sich die Stockscreener-App
23.08
4.82%
-1.1018
Schlusskurs vom Vortag:
$24.18
Offen:
$24.5
24-Stunden-Volumen:
400.04K
Relative Volume:
0.44
Marktkapitalisierung:
$1.37B
Einnahmen:
$13.05M
Nettoeinkommen (Verlust:
$-60.54M
KGV:
-19.89
EPS:
-1.16
Netto-Cashflow:
$-37.82M
1W Leistung:
-4.17%
1M Leistung:
-3.95%
6M Leistung:
-41.55%
1J Leistung:
-34.79%
1-Tages-Spanne:
$22.77
$24.66
1-Wochen-Bereich:
$22.77
$26.50
52-Wochen-Spanne:
$22.48
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
23.11 | 1.51B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.00 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.82 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.60 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.59 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Janux Therapeutics reaches clinical milestone in Merck TRACTr collaboration - TipRanks
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Yahoo Finance
Is Janux Therapeutics Inc. a growth stock or a value stockSuperior return velocity - Jammu Links News
What analysts say about Janux Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
What are the latest earnings results for Janux Therapeutics Inc.Build wealth faster with consistent investment plans - Jammu Links News
Should I hold or sell Janux Therapeutics Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What drives Janux Therapeutics Inc. stock priceExplosive trading growth - Jammu Links News
Janux Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with expert advice - Jammu Links News
How does Janux Therapeutics Inc. generate profit in a changing economyMaximize your gains with professional insights - Jammu Links News
Is Janux Therapeutics Inc. stock overvalued or undervaluedMaximize gains with data-driven stock picks - Jammu Links News
What makes Janux Therapeutics Inc. stock price move sharplyAccess powerful market insights for free - Jammu Links News
What are analysts’ price targets for Janux Therapeutics Inc. in the next 12 monthsUnlock your portfolio’s hidden potential - Jammu Links News
How does Janux Therapeutics Inc. compare to its industry peersAccelerated financial growth - Jammu Links News
Can Janux Therapeutics Inc. Regain Momentum After BreakdownReal Trader Watchlist of Hot Stocks Released - metal.it
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification - TipRanks
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
Why Janux Therapeutics Inc. stock attracts strong analyst attentionTriple Return Setup With Risk Control Explained - metal.it
Janux Therapeutics Receives Buy Rating from Leerink Partners Analyst Jeffrey La Rosa - AInvest
Why did JANX's operating expenses surge in Q3 2024? - AInvest
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Praise Ionis Pharmaceuticals and Janux Therapeutics for Bright Healthcare Futures - AInvest
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Combining machine learning predictions for Janux Therapeutics Inc. Yield Curve Outlook and Long-Term Implication Summary - metal.it
What is the dividend policy of Janux Therapeutics Inc. stockSuperior stock selection - Jammu Links News
Evercore ISI Analyst Maintains Buy Rating on Janux Therapeutics with $25.00 Price Target - AInvest
Janux Therapeutics Inc: Strategic Advancements and Strong Positioning in Oncology Drive Buy Rating - TipRanks
Adc Therapeutics Sa shares fall 1.83% after-hours following Janux Therapeutics' R&D Day press release. - AInvest
Why Intel Stock Is Plummeting Today - The Globe and Mail
What makes Janux Therapeutics Inc. stock attractive to long term investorsRapid-fire capital growth - Jammu Links News
Janux Therapeutics’ Strategic Expansion and Promising Pipeline Drive Buy Rating - TipRanks
Janux Therapeutics' Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating - AInvest
Janux Therapeutics Faces Trade Policy Challenges: Impact on Operations and Growth - TipRanks
Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating for Janux Therapeutics - TipRanks
Is Janux Therapeutics Inc. stock a growth or value playHigh-profit capital plays - Jammu Links News
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):